



PTO/SB/21 (09-04)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/660,115	
	Filing Date	September 10, 2003	
	First Named Inventor	Jonathan AXON	
	Art Unit	1624	
	Examiner Name	V. Balasubramanian	
Total Number of Pages in This Submission	3	Attorney Docket Number	219002029400

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input checked="" type="checkbox"/> Amendment/Reply (Response to Restriction Requirement -2 pages)  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/Incomplete Application  <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Receipt
<div>Remarks</div> <div>Customer No. 25225</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	MORRISON & FOERSTER LLP		
Signature			
Printed name	Kate H. Murashige		
Date	July 20, 2005	Reg. No.	29,959

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: July 20, 2005	Signature:  (Stacy L. Myers)



IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 7/20/05

Signature: Stacey L. Myers

(Stacey L. Myers)

Docket No.: 219002029400  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Jonathan AXON et al.

Confirmation No. 6854

Application No.: 10/660,115

Group Art Unit: 1624

Filed: September 10, 2003

Examiner: V. Balasubramanian

For: INHIBITORS OF TGF $\beta$

**RESPONSE TO RESTRICTION REQUIREMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This is in response to an Office action herein mailed 20 June 2005, time for response to which was set to expire 20 July 2005. Restriction between two groups was required.

Applicants elect, with traverse, the invention of Group II drawn to the compound of Formula 1 wherein Z is CR<sup>4</sup>. These are actually pyrimidine compounds; in order that there be no confusion, applicants wish to make clear that their election is to the compounds wherein Z is CR<sup>4</sup>, not the triazine compounds wherein Z is N.

This election is made with traverse because applicants consider pyrimidines and triazines substantially interchangeable in the context of the present invention. This is made clear from the definitions in the formula itself.

As to the election of species, applicants elect the species of Compound No. 9 shown on page 47 of the application.

Examination on the merits is now requested.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicant petitions for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 219002029400. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated:

*July 20, 2005*

Respectfully submitted,

By

*Kate H. Murashige*

Kate H. Murashige

Registration No.: 29,959

MORRISON & FOERSTER LLP

3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

(858) 720-5112